Rare cancer study seeks to unlock secrets of neuroendocrine tumors
NCT ID NCT05237934
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aims to collect tissue samples and health information from 300 adults with neuroendocrine neoplasms (NENs), including adrenocortical carcinoma. Researchers will follow participants over time to understand how these rare cancers grow and respond to treatments. The goal is to improve future care, not to test a new therapy directly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADRENOCORTICAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- One dose may not fit all: blood tests could tailor cancer drug dosing
- Can a new 'Nanobody' tracer outsmart standard scans for neuroendocrine cancers?
- Can a radioactive drug shrink Slow-Growing tumours?
- Can a Three-Drug cocktail shrink Hard-to-Treat neuroendocrine tumors?
- Liver tumors targeted directly: old pump, new drug
- Experimental drug targets Hard-to-Treat neuroendocrine cancers